KCT0004263
Recruiting
未知
Clinical performance study of breast cancer prognostic diagnosticsGenesWell™ BCT in Korean patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Samsung Medical Center
- Enrollment
- 500
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.1\. Selection criteria
- •1\.1\.1\. Criteria for Selection of Sample Providers
- •1\) hormone receptor positive (ER\+ and/or PR\+)
- •2\) Human epidermal growth factor receptor type2 negative (HER2\-)
- •3\) pN0 or pN1 is applicable
- •4\) Female patients
- •1\.1\.2\. Criteria for selecting remaining samples
- •1\) Residual samples containing the collected tissue with paraffin (FFPE residual samples)
- •2\) In case pathological samples that are not obstructed in future care are stored
Exclusion Criteria
- •1\.1\.1\. Exclusion Criteria for Sample Providers
- •1\) For hormone receptor negative (ER\- and PR\-)
- •2\) Human epidermal growth factor receptor type2 (HER2\+)
- •3\) pN2, or pN3 is applicable
- •1\.1\.2\. Exclusion Criteria for Residual Specimens
- •1\) Remaining samples not covered with paraffin (non\-FFPE residual samples)
- •2\) Pathologists have determined that the condition of the FFPE block is not available for clinical trials in tissue and pathology
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Verification of the effectiveness of breast cancer education for healthy peoplehealthy peopleJPRN-UMIN000046287Tokyo Medical and Dental Univ.300
Completed
Phase 2
Breast Cancer Study of Clinical Efficacy and Safty of Avastin with Paclitaxel in the 1st-taxane-lineJPRN-UMIN000007948Hiroshima University35
Active, not recruiting
Phase 1
Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®Breast CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002039-28-ESSandoz GmbH308
Completed
Phase 3
A study to evaluate the Efficacy and Safety of LA-EP2006 and Neulasta® in patients with breast cancer.CTRI/2012/10/003065Sandoz GmbH302
Active, not recruiting
Phase 1
Study to see if it is possible to guide tumorectomy in case of breast cancer by near-infrared fluorescence after intravenous injection of Indocyanine GreeImaging of tumours and their margins after intravenous injection ofIndocyanine Green to breast cancer patientsTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003268-19-BEJules Bordet Institute